Company GENFIT

Equities

GNFT

FR0004163111

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for GENFIT

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:05:02 26/04/2024 pm IST			5-day change	1st Jan Change
3.21 ^EUR	+1.58%		+1.58%	-9.32%

26/04	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	MT
24/04	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.

The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).

Number of employees: 159

EUR in Million	2022	Weight	2023	Weight	Delta
Research and Development of Innovative Medicines and Diagnostic Solutions 100.0 %	20	100.0 %	29	100.0 %	+41.45%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	20	100.0 %	29	100.0 %	+41.45%

Managers	Title	Age	Since
Pascal Prigent CEO	Chief Executive Officer	56	01/18/01
Jean-François Mouney FOU	Founder	68	01/99/01
Thomas Baetz DFI	Director of Finance/CFO	50	22/21/22
John Brozek CTO	Chief Tech/Sci/R&D Officer	47	-
Stefanie Magner CMP	Compliance Officer	43	01/16/01
Pascal Caisey COO	Chief Operating Officer	56	01/19/01
Carol L. Addy CTO	Chief Tech/Sci/R&D Officer	64	09/19/09
Meriam Kabbaj CTO	Chief Tech/Sci/R&D Officer	50	01/22/01
Dean Hum CTO	Chief Tech/Sci/R&D Officer	61	01/00/01
Jean-Christophe Marcoux IRC	Investor Relations Contact	47	01/15/01

Members of the board	Title	Age	Since
Jean-François Tiné BRD	Director/Board Member	67	04/21/04
Jean-François Mouney FOU	Founder	68	01/99/01
Florence Séjourné FOU	Founder	52	15/99/15
Xavier Guille des Buttes BRD	Director/Board Member	82	18/06/18
Catherine Larue BRD	Director/Board Member	68	16/17/16
Anne-Hélène Monsellato BRD	Director/Board Member	56	16/17/16
Katherine Kalin BRD	Director/Board Member	61	07/20/07
Eric Baclet BRD	Director/Board Member	64	07/20/07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,834,983	43,244,222 ( 86.77 %)	0	86.77 %

Name	Equities	%	Valuation
IPSEN 7.997 %	3,985,239	7.997 %	14 M €
Tang Capital Management LLC 4.917 %	2,450,404	4.917 %	9 M €
Biotech Avenir SAS 3.790 %	1,888,618	3.790 %	7 M €
Universite de Lille II Foundation 1.307 %	651,250	1.307 %	2 M €
Sunny Asset Management SA 0.2408 %	120,000	0.2408 %	432 864 €
Jean-François Mouney 0.0935 %	46,594	0.0935 %	168 074 €
Meeschaert Asset Management SA 0.0761 %	37,911	0.0761 %	136 753 €
Ecofi Investissements SA 0.0723 %	36,042	0.0723 %	130 011 €
OFI Invest Asset Management SA 0.0625 %	31,128	0.0625 %	112 285 €
Pascal Prigent 0.0616 %	30,708	0.0616 %	110 770 €

Name	Equities	%	Valuation
Tang Capital Management LLC 0.9621 %	479,441	0.9621 %	2 M €
Optiver Holding BV 0.1653 %	82,359	0.1653 %	293 198 €
Morgan Stanley & Co. International Plc 0.0617 %	30,763	0.0617 %	109 516 €
Millennium Management LLC 0.0568 %	28,310	0.0568 %	100 784 €
Old Mission Capital LLC 0.0249 %	12,428	0.0249 %	44 244 €
UBS Securities LLC 0.002282 %	1,137	0.002282 %	4 048 €
RhumbLine Advisers LP 0.001360 %	678	0.001360 %	2 414 €
Advisory Services Network LLC 0.000201 %	100	0.000201 %	356 €
Qube Research & Technologies Ltd. (France) 0.000197 %	98	0.000197 %	349 €

Genfit SA

Parc Eurasante 885, Avenue Eugène Avinée

59120, Loos

+33 3 20 16 40 00

http://www.genfit.com

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.21 EUR

Average target price

9.38 EUR

Spread / Average Target

+192.21%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENFIT	-9.32%	170M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research